Researcher Profile

H.S. Rugo

Publications

3,178

Citations

Co-Authors

Active Years

Publications

Open Access Journal Article ESMO Open Mar 01, 2026

Imlunestrant plus abemaciclib versus fulvestrant plus abemaciclib in ER-positive, HER2-negative advanced breast cancer: an indirect treatment comparison of three phase III trials

K. Jhaveri · F.C. Bidard · K. Kalinsky · P. Neven +8 more

10.1016/j.esmoop.2026.106091

Open Access Journal Article Annals of Oncology Feb 01, 2026

Overall survival with abemaciclib in early breast cancer

S. Johnston · M. Martin · J. O’Shaughnessy · R. Hegg +23 more

10.1016/j.annonc.2025.10.005 20 citations

Open Access Journal Article Annals of Oncology Dec 01, 2025

Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study

B. Pistilli · K. Jhaveri · S.-A. Im · S. Pernas +16 more

10.1016/j.annonc.2025.12.017 2 citations

Open Access Journal Article ESMO Open May 01, 2024

198P Pembrolizumab plus olaparib vs pembrolizumab plus chemotherapy after induction with pembrolizumab plus chemotherapy for locally recurrent inoperable or metastatic TNBC: Patient-reported outcomes from KEYLYNK-009

A. Llombart Cussac · H.S. Rugo · M.E. Robson · S-A. Im +16 more

10.1016/j.esmoop.2024.103220 4 citations

Open Access Journal Article Annals of Oncology Apr 01, 2022

Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

C.E. Geyer · W.M. Sikov · J. Huober · H.S. Rugo +17 more

10.1016/j.annonc.2022.01.009 181 citations

Open Access Journal Article Annals of Oncology Jun 01, 2022

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study

H.S. Rugo · J. O’Shaughnessy · F. Boyle · M. Toi +18 more

10.1016/j.annonc.2022.03.006 116 citations

Open Access Journal Article Annals of Oncology Sep 01, 2021

Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

A. Bardia · S.M. Tolaney · K. Punie · D. Loirat +23 more

10.1016/j.annonc.2021.06.002 254 citations

Open Access Journal Article Annals of Oncology Aug 01, 2021

First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis

L.A. Emens · S. Adams · C.H. Barrios · V. Diéras +12 more

10.1016/j.annonc.2021.05.355 392 citations

Open Access Journal Article Annals of Oncology Feb 01, 2021

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

F. André · E.M. Ciruelos · D. Juric · S. Loibl +16 more

10.1016/j.annonc.2020.11.011 518 citations

Open Access Journal Article Annals of Oncology Nov 01, 2020

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

J.K. Litton · S.A. Hurvitz · L.A. Mina · H.S. Rugo +16 more

10.1016/j.annonc.2020.08.2098 358 citations

Open Access Journal Article Annals of Oncology Mar 01, 2019

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study

S. Adams · S. Loi · D. Toppmeyer · D.W. Cescon +16 more

10.1093/annonc/mdy518 531 citations

Open Access Journal Article Annals of Oncology Mar 01, 2019

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study

S. Adams · P. Schmid · H.S. Rugo · E.P. Winer +17 more

10.1093/annonc/mdy517 678 citations

Open Access Journal Article Annals of Oncology Sep 01, 2018

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

J. Ettl · R.G.W. Quek · K.-H. Lee · H.S. Rugo +14 more

10.1093/annonc/mdy257 124 citations

Publication Timeline

2026

2025

2024

2022

2021

2020

2019

2018

Frequent Co-Authors

6×

4×

4×

4×

4×

3×

3×

3×

3×

3×